<?xml version="1.0" encoding="UTF-8"?>
<p id="para0029">Of note, 2 observational case-control analyses reported no effect of preadmission exposure to either antiplatelet therapy or anticoagulant therapy prescribed for other clinical indications on presenting acute respiratory distress syndrome, intensive care unit admission rates, or mortality rates for patients admitted with COVID-19.
 <xref rid="bib0052" ref-type="bibr">
  <sup>52</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0053" ref-type="bibr">
  <sup>53</sup>
 </xref> However, these analyses were of nonrandomized cohorts comprised of patients already hospitalized and prone to potential bias from the underlying clinical conditions for which the antithrombotic was prescribed. A large prospective, randomized trial of outpatient anticoagulant prophylaxis such as PREVENT-HD in addition to the other large trials will provide high-quality evidence of the value of this preventative strategy.
</p>
